(BMC cancer[TA])
20,754 results
  • Real-world treatment pattern and clinical outcomes in Chinese NSCLC patients with KRAS G12C mutation. [Journal Article]
    BMC Cancer. 2026 Jul 30; 26(1).Shen L, Gao Y, … Li ZBC
  • CONCLUSIONS: This real-world study provides a comprehensive characterization of the clinical management and outcomes of KRAS G12C-mutated NSCLC in China in the pre-KRAS G12C inhibitor treatment era. First-line chemo-immunotherapy provides independent survival benefit over chemotherapy, with immune monotherapy reserved for carefully selected PD-L1 high cases. STK11 co-mutation predicts extremely poor outcomes (median PFS 3.75 months), representing an unmet clinical need. This study provides an essential historical reference for quantifying their real-world clinical impact.